Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | RXRA | P19793 | 1/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | MPC2 | O95563 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1220736 | 0.89 | PPARG (0.75) | PPARGCYP3A4RXRAFFAR1PPARA | |
| SCHEMBL12521708 | 0.86 | PPARG (0.66) | PPARGCYP3A4RXRAFFAR1PPARA | |
| SCHEMBL8791585 | 0.86 | PPARG (0.64) | PPARGCYP3A4RXRAFFAR1PPARA | |
| SCHEMBL8792201 | 0.83 | PPARG (0.80) | PPARGCYP3A4RXRAFFAR1PPARA | |
| SCHEMBL18541507 | 0.83 | PPARG (0.69) | PPARGCYP3A4RXRAFFAR1PPARA | |
| SCHEMBL6358262 | 0.83 | PPARG (0.69) | PPARGCYP3A4RXRAFFAR1PPARA | |
| SCHEMBL19828517 | 0.83 | PPARG (0.69) | PPARGCYP3A4RXRAFFAR1PPARA | |
| SCHEMBL13524844 | 0.81 | PPARG (0.75) | PPARGCYP3A4RXRAFFAR1PPARA | |
| SCHEMBL8196242 | 0.80 | PPARG (0.66) | PPARGCYP3A4RXRAFFAR1PPARA | |
| SCHEMBL10853494 | 0.80 | PPARG (0.67) | PPARGCYP3A4RXRAFFAR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0508740-B1 | Thiazolidinedione derivatives, their production and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-10-01 | — | — | EP | claimed |
| US-5183823-A | PYRIDINE N-OXIDE COMPOUNDS WHICH ARE USEFUL AS HYPOGLYCEMIC AND HYPOLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-02 | — | — | US | claimed |
| EP-0508740-A1 | Thiazolidinedione derivatives, their production and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-14 | — | — | EP | claimed |
| WO-2011091033-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| EP-0508740-B1 | Thiazolidinedione derivatives, their production and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-10-01 | — | — | EP | disclosed |
| EP-0612730-B1 | O-aryl ethers of morphinans | HOFFMANN LA ROCHE (CH) | 1997-07-02 | — | — | EP | disclosed |
| EP-0612730-A1 | O-aryl ethers of morphinans | F. HOFFMANN-LA ROCHE AG (CH) | 1994-08-31 | — | — | EP | disclosed |
| US-5183823-A | PYRIDINE N-OXIDE COMPOUNDS WHICH ARE USEFUL AS HYPOGLYCEMIC AND HYPOLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-02 | — | — | US | disclosed |
| EP-0508740-A1 | Thiazolidinedione derivatives, their production and their use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | PPARG, PPARA, PPARD | PPARG 1/4885CYP3A4 4831/4885RXRA 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.